Navigation Links
EnWave Announces Collaboration and Initial Testing Results with Danisco AS
Date:4/7/2009

s using Radiant Energy Vacuum technology under its bioREVTM, freezeREV, nutraREVTM and powderREV brands. REV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include dry vaccines and antibodies. More information about EnWave is available at www.enwave.net.

    EnWave Corporation
    Mr. John McNicol
    President & Co-CEO

This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. The forward-looking statements in this press release include: "EnWave intends to" and "EnWave expects". These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's powderREV technology can or will improve processes in the food culture industry; even if the Company's powderREV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's powderREV technology.

    The TSX Venture Exchange has neither approved nor disapproved the
    information contained herein.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.


'/>"/>
SOURCE EnWave Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
2. Microbix Announces A New Technology Platform For The SST Project
3. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
4. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
5. Immunotech Laboratories Announces South American Strategy
6. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
7. ChromaDex Announces 2008 Year End Financial Results
8. China Agri-Business Announces 2008 Operating Results
9. Verenium Announces Organizational Changes
10. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
11. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, ... Partners, today announced the hiring of veteran equity analyst ... equity analyst. Mr. Butler will focus on the biotech/biopharma ... team a wealth of experience and a broad network ... , Senior Managing Director and Head of Equities at ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 ... state of the global isotope ratio mass spectrometer industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/27/2014)... Tris Pharma, a specialty pharmaceutical company focused ... it has been selected as an award winner in ... Awards for Excellence competition in the Business Expansion ... judges from SCORE (Counselors to America,s Small Business) and ... at a gala event to be held on October ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced the close of previously reported agreements to sell ... Preferred Stock and warrants to purchase shares of its ...
... Agreement on Molecular Tests... -- GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010, ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 2QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 4QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 5QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 6QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 7QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 8QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 9QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 10US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:8/28/2014)... pose a significant health risk to people with asthma according ... Allergy and Clinical Immunology . , By critically reviewing the ... has found that the presence of several types of mould ... as increasing the likelihood of developing the condition. , The ... of Exeter Medical School and is the first time all ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
(Date:8/27/2014)... bears, giant ground sloths, saber-toothed cats and American camels ... at the end of the Pleistocene period. The cause ... scientists who, until recently, could only speculate as to ... Barbara,s James Kennett, professor emeritus in the Department of ... played a major role in the extinction. Their hypothesis ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3
... News headlines are filled with discussion and ... Change Conference in Copenhagen. As expected, the ... has focused on traditional environmental measures - regulations ... sources, etc. A new book Paradise Regained: ...
... PHILADELPHIA People with the heritable disorder of ... to develop basal cell carcinoma of the skin may ... According to results of a placebo-controlled, randomized, double-blind, ... in inhibiting the development of basal cell carcinomas in ...
... plan to put two and two together in a study ... Two traits that impact corn will be examined by ... products at the farm level. Drought tolerance and aflatoxin ... Research scientists who have been awarded a $500,000 grant for ...
Cached Biology News:Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Celebrex inhibited the burden of skin cancer in high-risk patients 2Genes for drought-tolerance, aflatoxin may mingle to boost corn production 2
... synthetic peptide whose sequence is from rat SCAMP 5. The ... - N(217) - Q - P - Q - T - ... - N - Y - T - Y - S - ... control experiments with the polyclonal antibody that reacts with this product ...
... of IgY) , After we receive your antigen ... the appropriate number of chickens and begin to ... collected (usually over a period of 3-5 days), ... total of four injections into the breast muscle. ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Biology Products: